RxDoctor Payments Data

John Nguyen, MD

Cardiovascular Disease · Cypress, TXNPI 1831125319

Payments from drug & device makers

$7,558in general payments, 2019–2025

Across 308 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Penumbra, Inc.$1K
  • Boston Scientific$859
  • Amgen$824
  • Johnson & Johnson$608
  • Medtronic$452
  • Novartis$441
  • plus $3K from 36 others

What the payments were for

  • Travel & lodging$7079%
  • Food & beverage$6,81690%
  • Education$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,558 in reported general payments places this provider in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$765,073
Medicare patients
574
Services billed
3,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban307$315,227
XareltoRivaroxaban231$221,595
EntrestoSacubitril/Valsartan64$71,522
BrilintaTicagrelor29$22,902
MultaqDronedarone Hcl12$20,125
Ranolazine ErRanolazine118$12,173
FarxigaDapagliflozin Propanediol11$9,943
Praluent PenAlirocumab14$9,528
EdarbiAzilsartan Medoxomil13$6,854
Amiodarone Hcl148$6,325
VascepaIcosapent Ethyl12$5,956
Icosapent Ethyl23$4,617
Nifedipine ErNifedipine136$4,376
Flecainide Acetate70$3,203
Losartan Potassium352$3,126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$326$315,227307 claims
Johnson & JohnsonXarelto$608$221,595231 claims
NovartisEntresto$441$71,52264 claims
AstraZenecaBrilinta, Farxiga$206$32,84540 claims
Sanofi-aventis U.S. LLCMultaq$121$20,12512 claims
Arbor Pharmaceuticals, Inc.Edarbi$76$6,85413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Cypress

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →